{
    "clinical_study": {
        "@rank": "53687", 
        "arm_group": {
            "arm_group_label": "Single-Arm Fixed-Sequence", 
            "arm_group_type": "Experimental", 
            "description": "Subjects will receive two different interventions in fixed-sequence two-period study.  In the first period the subjects will receive a single-dose of palbociclib.  In the second period, subjects will receive 12 days of rifampin and a single dose of palbociclib on day 8.  In both periods, subjects will undergo pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose."
        }, 
        "brief_summary": {
            "textblock": "This study will compare the plasma pharmacokinetics of a single 125mg oral dose of\n      palbociclib in the presence and absence of rifampin-mediated enzyme induction in a\n      fixed-sequence two-period study."
        }, 
        "brief_title": "A Study To Investigate The Drug-Drug Interaction Potential Of Rifampin OnThe Investigational Agent Palbociclib (PD-0332991)", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy males or females of non-childbearing potential\n\n          -  body mass index between 17.5-30.5 kg/m2 with a total body weight greater than 50kg\n\n        Exclusion Criteria:\n\n          -  Evidence or history of any clinically significant physiologic, psychological, or\n             medical conditions\n\n          -  a positive drug screen or alcohol breath test\n\n          -  a baseline ECG demonstrating a QTc>450msecs or a QRS interval >120msecs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01953731", 
            "org_study_id": "A5481017"
        }, 
        "intervention": [
            {
                "arm_group_label": "Single-Arm Fixed-Sequence", 
                "description": "In period 1, patients will receive a single 125mg oral dose of palbociclib alone.  Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.\nIn period 2, subjects will receive 12 daily oral doses of 600mg of rifampin and a single 125mg oral dose of palbociclib on day 8.  Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.", 
                "intervention_name": "Palbociclib", 
                "intervention_type": "Drug", 
                "other_name": "palbociclib, PD-0332991"
            }, 
            {
                "arm_group_label": "Single-Arm Fixed-Sequence", 
                "description": "In period 2, subjects will receive 12 daily oral doses of 600mg of rifampin and a single 125mg oral dose of palbociclib on day 8.  Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.", 
                "intervention_name": "Rifampin", 
                "intervention_type": "Drug", 
                "other_name": "palbociclib, PD-0332991, rifampin, rifampicin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rifampin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "palbociclib", 
            "PD-0332991", 
            "rifampin", 
            "drug-drug interaction study"
        ], 
        "lastchanged_date": "January 16, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5481017&StudyName=A%20Study%20To%20Investigate%20The%20Drug-Drug%20Interaction%20Potential%20Of%20Rifampin%20OnThe%20Investigational%20Agent%20Palbociclib%20%28PD-0332991%29%0A"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06511"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Open-Label Fixed-Sequence 2-Period Study To Investigate The Effect Of Multiple Doses Of Rifampin On Palbociclib (PD-0332991) Pharmacokinetics In Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).", 
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]", 
                "safety_issue": "No", 
                "time_frame": "0-120 hours post-dose"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "0-120 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01953731"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "0-120 hours post-dose"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "0-120 hours post-dose"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "0-120 hours post-dose"
            }, 
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.  Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling.  Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.", 
                "measure": "Apparent Oral Clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "0-120 hours post-dose"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.", 
                "measure": "Apparent Volume of Distribution (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "0-120 hours post-dose"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}